Low impact
Cellular Immunotherapy for Prostate Cancer
Blue Cross & Blue Shield of Mississippi·Identified Jun 20, 2026
HCPCS Q2043 is officially defined as "Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion." HCPCS Q2043 is referenced in 1 tracked payer policy change from Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q2043 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.